Last updated on January 2020

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research


Brief description of study

Primary Objective:

To demonstrate equivalence of Gan & Lee Insulin Glargine Injection and Lantus in terms of immunogenicity

Secondary Objective:

Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26

Clinical Study Identifier: NCT03371108

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.